米国における多発性硬化症および疾患修正療法の使用率 (2011年−2021年)
Jieni Li1, George J Hutton2, Rajender R Aparasu1
1Department of Pharmaceutical Health Outcomes and Policy, University of Houston College of Pharmacy, Houston, TX, USA; Population Health Outcomes and Pharmacoepidemiology Education and Research (P-HOPER Center), University of Houston College of Pharmacy, Houston, TX, USA.
まとめ
65歳以上の米国人の多発性硬化症 (MS) の罹患率は,2011年から2021年にかけて15%以上増加した. この高齢者の半数以上は 病気を修正する治療法 (DMT) を用いており 専門的な高齢者治療の必要性が増していることを示しています
科学分野:
- 高齢者医療
- 神経学
- 流行病学について
背景:
- 多発性硬化症 (MS) の患者の寿命が長くなっています.
- その結果,高齢者の集団に 増えてくるMS患者数が増えています
研究 の 目的:
- 米国における高齢者 (65歳以上) の多発性硬化症 (MS) の流行を調査する.
- この特定の集団における疾患修正療法 (DMT) の利用を調査する.
主な方法:
- 医療保険料請求のデータ分析
- データ収集は2011年から2021年まで10年間続いた.
- 65歳以上の人口を中心に
主要な成果:
- 高齢者のMSの罹患率は2011年から2021年の間に15.49%増加しました.
- 2021年の流行率は10万人あたり243.17でした.
- 高齢化中のMS人口は主に女性 (75%) と白人 (90%) であった.
- MSの高齢者の50%以上は,主にインターフェロンベータとグラティラマーアセテートを処方された.
結論:
- 米国では高齢者の間で多発性硬化症 (MS) の罹患率が増加しています
- この集団の有意な割合は 病気を修正する治療法 (DMT) を利用しています
- 多発性硬化症の患者に合わせた 高齢者の介護サービスの強化の必要性が明らかになりました
関連する概念動画
Prevalence and Incidence
790
In statistical epidemiology and health sciences, two essential metrics—prevalence and incidence—are fundamental for understanding disease dynamics within a population. These measures enable public health officials, epidemiologists, and researchers to assess the burden of diseases, allocate resources effectively, and design impactful public health policies and interventions.
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
790
Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
Myasthenia Gravis: Overview and Treatment
1.9K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.9K
Parkinson's Disease: Overview
702
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
702
Parkinson's Disease: Treatment
376
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
376
Diagnostic and Statistical Manual of Mental Disorders (DSM)
141
The Diagnostic and Statistical Manual of Mental Disorders (DSM) serves as the primary classification system for mental health disorders, providing standardized diagnostic criteria for clinicians and researchers. First published by the American Psychiatric Association (APA) in 1952, the DSM has undergone several revisions to reflect evolving psychiatric understanding. The fifth edition, DSM-5, released in 2013, introduced key updates that expanded diagnostic categories and modified diagnostic...
141


